Literature DB >> 28189451

Personalized medicine: Enhancing our understanding of pediatric growth with analytic morphomics.

Calista M Harbaugh1, Peng Zhang2, Brianna Henderson3, Brian A Derstine2, Sven A Holcombe2, Stewart C Wang4, Carla Kohoyda-Inglis2, Peter F Ehrlich3.   

Abstract

BACKGROUND/
PURPOSE: Analytic morphomics is being used to identify 3-D biologic measures with superior clinical utility and risk stratification over traditional factors such as age, height, and weight. The purpose of this study is to define age and gender specific Pediatric Reference Analytic Morphomics Population (PRAMP™) growth charts.
METHODS: This retrospective study population contains 2591 individual CT scans of a normative reference population of males and females (1-20years old). Growth curves were constructed at the 5th, 25th, 50th, 75th, and 95th quantiles for morphomic variables, including psoas muscle area, trabecular bone density, and visceral fat area by age and gender.
RESULTS: Total psoas muscle area increases over time until late adolescence. Trabecular bone density remains stable until adolescence, decreases during adolescence, and increases in young adulthood. Visceral fat area increases over time with greater variation between the 5th and 95th percentile with increasing age.
CONCLUSIONS: The PRAMP™ data have been used to construct age- and sex-specific reference growth curves. This may be used to better define "abnormal" in efforts to create unique risk-categorization algorithms specific to particular clinical and global health investigations. LEVEL OF EVIDENCE: Level II.
Copyright © 2017 Elsevier Inc. All rights reserved.

Keywords:  Analytic morphomics; Cross-sectional imaging; Growth charts

Mesh:

Year:  2017        PMID: 28189451     DOI: 10.1016/j.jpedsurg.2017.01.030

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

1.  Computed Tomography Evidence of Psoas Muscle Atrophy Without Concomitant Tendon Wasting in Early Sepsis.

Authors:  Carrie A Kubiak; Kavitha Ranganathan; Niki Matusko; Jon A Jacobson; Stewart C Wang; Pauline K Park; Benjamin L Levi
Journal:  J Surg Res       Date:  2018-10-11       Impact factor: 2.192

2.  Sarcopenia is highly prevalent in children with autoimmune liver diseases and is linked to visceral fat and parent-perceived general health.

Authors:  Antoinette A Amevor; Toshifumi Yodoshi; Andrew T Trout; Jonathan R Dillman; Ruchi Singh; Ryan Jarvis; Lin Fei; Chunyan Liu; Amy Taylor; Alexander Miethke; Marialena Mouzaki
Journal:  Liver Int       Date:  2021-11-29       Impact factor: 8.754

3.  Paediatric reference values for total psoas muscle area.

Authors:  Eberhard Lurz; Hiten Patel; Gerald Lebovic; Claudia Quammie; Jessica P Woolfson; Manuela Perez; Amanda Ricciuto; Paul W Wales; Binita M Kamath; Govind B Chavhan; Peter Jüni; Vicky L Ng
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-01-09       Impact factor: 12.910

Review 4.  Sarcopenia in Children with Solid Organ Tumors: An Instrumental Era.

Authors:  Annika Ritz; Eberhard Lurz; Michael Berger
Journal:  Cells       Date:  2022-04-09       Impact factor: 7.666

5.  Reference values for MRI-derived psoas and paraspinal muscles and macroscopic fat infiltrations in paraspinal muscles in children.

Authors:  Kacper Marunowski; Dominik Świętoń; Włodzimierz Bzyl; Małgorzata Grzywińska; Piotr Bandosz; Dmitry Khrichenko; Maciej Piskunowicz
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-07-19       Impact factor: 12.063

6.  Higher Mortality in Pediatric Liver Transplant Candidates With Sarcopenia.

Authors:  Julia M Boster; Lorna P Browne; Zhaoxing Pan; Wenru Zhou; Peter F Ehrlich; Shikha S Sundaram
Journal:  Liver Transpl       Date:  2021-06       Impact factor: 6.112

7.  Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients.

Authors:  Kung-Hao Liang; Peng Zhang; Chih-Lang Lin; Stewart C Wang; Tsung-Hui Hu; Chau-Ting Yeh; Grace L Su
Journal:  Dig Dis Sci       Date:  2019-11-02       Impact factor: 3.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.